Precipio (PRPO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on June 17, 2025, with stockholders able to participate and vote online using a 16-digit control number.
Stockholders of record as of April 21, 2025, are eligible to vote on the election of directors and ratification of the independent auditor.
Proxy materials and the 2024 Annual Report are available online, with options for paper copies upon request.
The Board encourages prompt voting to ensure quorum and reduce solicitation costs.
Voting matters and shareholder proposals
Proposal One: Election of Ilan Danieli and David S. Cohen as Class I directors for terms expiring in 2028.
Proposal Two: Ratification of CBIZ CPAs, P.C. as the independent registered public accounting firm for 2025.
Stockholders may submit additional proposals for future meetings, following specific advance notice and SEC rules.
Board recommends voting FOR both proposals.
Board of directors and corporate governance
The Board consists of seven members, with a majority being independent and all committees fully independent.
Directors are divided into three classes, serving staggered three-year terms.
Board diversity, refreshment, and succession planning are emphasized, with a focus on skills, experience, and diversity.
The Chairperson is independent, and executive sessions are held regularly.
Committees include Audit, Compensation, and Nominating & Corporate Governance, each meeting multiple times in 2024.
Latest events from Precipio
- Q2 2025 net sales up 27%, gross margin at 43%, with positive net income but ongoing risks.PRPO
Q2 202527 Jan 2026 - Q1 2025 revenue up 44% to $4.9M, gross margin 43%, net loss narrowed, but risks remain.PRPO
Q1 202527 Jan 2026 - Q3 2025 saw 30% revenue growth, positive EBITDA, 44% margin, but going concern risk persists.PRPO
Q3 202527 Jan 2026 - Net sales and pathology revenues rose, but losses and liquidity concerns remain.PRPO
Q3 202427 Jan 2026 - Q2 2024 revenue up 26% to $4.4M, losses narrowed, but going concern risks remain.PRPO
Q2 202427 Jan 2026 - Achieved Q4 break-even, strong revenue growth, and set ambitious 2025 expansion targets.PRPO
Q4 202426 Dec 2025 - Annual proxy covers director elections and key proposals, with no capital structure changes.PRPO
Proxy Filing1 Dec 2025 - Shareholders must vote promptly to ensure quorum and avoid costly meeting delays.PRPO
Proxy Filing1 Dec 2025 - Shareholder votes needed by 11 p.m. ET to avoid costly adjournment of annual meeting.PRPO
Proxy Filing1 Dec 2025